Therapy News and Research

RSS

Major response to preoperative therapy increases survival in pancreatic cancer patients

Cancer of the pancreas--a glandular organ that lies behind the stomach and secretes vital enzymes and hormones--seldom is detected in early stages, making treatment difficult and survival statistics particularly grim. However, new research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

29 May 2010

Women who undergo bilateral oophorectomy tend to have smaller tumors

More than half a million women in the United States undergo a hysterectomy each year and approximately half of those surgeries include removal of the ovaries. Researchers know that removing a woman's ovaries is associated with a reduction in the risk of developing breast cancer, but it has not been clear whether those cancers that do arise in these women differ from breast cancers in the general population.

29 May 2010

Clinical abstracts on Urologix' Cooled ThermoTherapy selected for presentation at AUA's GUS meeting

Urologix®, Inc., a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced the selection of two clinical abstracts for podium presentation at the American Urological Association (AUA) 2010 Annual Meeting's sub-specialty society, the Geriatric Urological Society (GUS) meeting.

29 May 2010

EDAP to showcase Ablatherm-HIFU technology and Sonolith i-sys lithotripter at AUA 2010 Annual Meeting

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced it will have a strong presence in both the exhibition and the scientific program at the American Urological Association (AUA) 2010 Annual Meeting, being held May 29 – June 3, 2010 in San Francisco. EDAP will showcase its Ablatherm-HIFU technology and Sonolith i-sys lithotripter at its exhibition booth # 1938 of the Moscone Convention Center.

29 May 2010

RNAi therapy shuts down gene critical to RSV, prevents virus replication

John DeVincenzo, MD, professor and researcher in the Departments of Pediatrics and Molecular Sciences at the University of Tennessee Health Science Center (UTHSC), has proven for the first time that a totally new concept in drug design can be used to treat human disease. Dr. DeVincenzo, who also serves as a children's infectious diseases specialist at Le Bonheur Children's Hospital, conducted his study at the Children's Foundation Research Center, a UT Health Science Center partner located at Le Bonheur.

29 May 2010

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.

29 May 2010

Patients Medical offers innovative stroke treatments to live longer, healthier life

Patients Medical, a leading integrative medical center in New York City, offers innovative stroke treatments such as hyperbaric oxygen therapy, acupuncture, diet therapy and customized intravenous nutrition drips. Daniel Silverstein, MD, holistic physician, recommends focusing on prevention to avoid a stroke and to live a longer, healthier life.

29 May 2010

New, non-controversial source of stem cells can form heart muscle cells, repair heart damage

A new and non-controversial source of stem cells can form heart muscle cells and help repair heart damage, according to results of preliminary lab tests reported in Circulation Research: Journal of the American Heart Association.

29 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

Study highlights need for earlier diagnosis and treatment of HIV

Despite growing evidence that the earlier people are diagnosed with HIV and get access to care, the better their clinical outcomes, many HIV-infected people in the United States and Canada are not receiving the care they need early enough.

29 May 2010

Recent releases in Global Health

A Lancet Infectious Diseases Leading Edge article examines the history of the global efforts to control polio and the challenges associated with targets to globally eradicate the disease. "The eradication of polio seems imminent, but with so few cases, there is a temptation to think an acceptable level of infection has been achieved. Not so.

29 May 2010

DFG approves establishment of twelve new CRCs

The Deutsche Forschungsgemeinschaft has approved the establishment of twelve new Collaborative Research Centres beginning 1 July 2010. This was decided by the responsible Grants Committee at its spring meeting in Bonn. The new CRCs will initially be funded for four years with a total of 112 million euros (including a 20% programme allowance for indirect project costs).

29 May 2010

Pancreatic cancer patients with circulating tumor cells tend to have worse outcomes: Study

Fox Chase Cancer Center investigators find that pancreatic cancer patients who have circulating tumor cells tend to have worse outcomes than patients without circulating tumor cells. Additionally, the team has uncovered evidence that not all circulating tumor cells are the same, and some may predict worse outcomes than others.

29 May 2010

New GreenLight XPS Laser System launched for treatment of BPH

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the launch and immediate availability of its new GreenLight XPS (Xcelerated Performance System) for laser treatment of benign prostatic hyperplasia or enlarged prostate.

29 May 2010

2010 Quality Index Reports on Ontario's Cancer System

Wait times for cancer radiation treatment continued their decline across Ontario during 2009, despite a more than 10 per cent increase in the number of patients receiving treatment, according to the 2010 Cancer System Quality Index report issued today.

28 May 2010

Novel imaging system helps visualize and monitor cellular immune responses of transplanted tissue in real time

A group of "color-coded" laboratory mice are providing researchers with a novel way of tracking T-cells, enabling them to visualize and monitor the cellular immune responses of transplanted tissue in real time. The new imaging system is described in the June issue of Nature Medicine, which appears on-line this week.

28 May 2010

Helicobacter pylori's helical shape helps it colonize the stomach

The bacterium Helicobacter pylori, which lives in the human stomach and is associated with ulcers and gastric cancer, is shaped like a corkscrew, or helix. For years researchers have hypothesized that the bacterium's twisty shape is what enables it to survive - and thrive - within the stomach's acid-drenched environment, but until now they have had no proof.

28 May 2010

PuriCore sales decreases 9.9% to $10.0 million for first-quarter 2010

PuriCore, the water-based clean technology company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today issued its Interim Management Statement covering the period January 1, 2010, to March 31, 2010.

28 May 2010

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

VIVUS, Inc. today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 inhibitor therapy being investigated for the treatment of erectile dysfunction, will be presented next Tuesday at the American Urological Association 2010 Annual Meeting in San Francisco, California.

28 May 2010

PuriCore revenue increases 28% to $40.0 million for year ending December 31, 2009

PuriCore, the water-based clean technology company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announced its Final Results for the year ending December 31, 2009, and the availability of its 2009 annual report on its website.

28 May 2010

Therapy News and Research

Major response to preoperative therapy increases survival in pancreatic cancer patients

Women who undergo bilateral oophorectomy tend to have smaller tumors

Clinical abstracts on Urologix' Cooled ThermoTherapy selected for presentation at AUA's GUS meeting

EDAP to showcase Ablatherm-HIFU technology and Sonolith i-sys lithotripter at AUA 2010 Annual Meeting

RNAi therapy shuts down gene critical to RSV, prevents virus replication

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Patients Medical offers innovative stroke treatments to live longer, healthier life

New, non-controversial source of stem cells can form heart muscle cells, repair heart damage

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

Study highlights need for earlier diagnosis and treatment of HIV

Recent releases in Global Health

DFG approves establishment of twelve new CRCs

Pancreatic cancer patients with circulating tumor cells tend to have worse outcomes: Study

New GreenLight XPS Laser System launched for treatment of BPH

2010 Quality Index Reports on Ontario's Cancer System

Novel imaging system helps visualize and monitor cellular immune responses of transplanted tissue in real time

Helicobacter pylori's helical shape helps it colonize the stomach

PuriCore sales decreases 9.9% to $10.0 million for first-quarter 2010

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

PuriCore revenue increases 28% to $40.0 million for year ending December 31, 2009

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News